BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F12%3A%230001682" target="_blank" >RIV/65269705:_____/12:#0001682 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14330/12:00059688
Result on the web
<a href="http://dx.doi.org/10.3109/10428194.2012.656104" target="_blank" >http://dx.doi.org/10.3109/10428194.2012.656104</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3109/10428194.2012.656104" target="_blank" >10.3109/10428194.2012.656104</a>

Result language
angličtina
Original language name
BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response
Original language description
Chronic myeloid leukemia (CML) is a myeloproliferative disosrder of hematopoietic stem cells that is characterized by the presence of the BCR-ABL fusion gene, which eneodes the constitutively active BCR-ABL tyrosine kinase.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/2B06052" target="_blank" >2B06052: Determination of markers, screening and early diagnostics of cancer diseases using highly automated processing of multidimensional biomedical images</a><br>
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)